SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $554 | -16.6% | 458 | 0.0% | 0.00% | – |
| Q2 2023 | $664 | -99.7% | 458 | -98.1% | 0.00% | – |
| Q1 2022 | $215,000 | -30.2% | 24,740 | +28.4% | 0.00% | – |
| Q4 2021 | $308,000 | -14.7% | 19,261 | -1.7% | 0.00% | – |
| Q3 2021 | $361,000 | +39.4% | 19,590 | +5.5% | 0.00% | – |
| Q2 2021 | $259,000 | -4.4% | 18,565 | +0.7% | 0.00% | – |
| Q1 2021 | $271,000 | -27.3% | 18,439 | -4.0% | 0.00% | -100.0% |
| Q4 2020 | $373,000 | +128.8% | 19,216 | +31.2% | 0.00% | – |
| Q3 2020 | $163,000 | -32.9% | 14,648 | -18.3% | 0.00% | – |
| Q2 2020 | $243,000 | +82.7% | 17,929 | +9.2% | 0.00% | – |
| Q1 2020 | $133,000 | -10.1% | 16,417 | +6.7% | 0.00% | – |
| Q4 2019 | $148,000 | -6.9% | 15,387 | +2.3% | 0.00% | – |
| Q3 2019 | $159,000 | +1.9% | 15,042 | +10.9% | 0.00% | – |
| Q2 2019 | $156,000 | +11.4% | 13,561 | +24.5% | 0.00% | – |
| Q1 2019 | $140,000 | +125.8% | 10,893 | +8.8% | 0.00% | – |
| Q4 2018 | $62,000 | – | 10,010 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |